Relevant bibliographies by topics / Preclinical pharmacokinetics

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Preclinical pharmacokinetics'

Author: Grafiati
Published: 4 June 2021
Last updated: 3 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Preclinical pharmacokinetics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Preclinical pharmacokinetics"

1

Song, Wei, Meilin Liu, Junjun Wu, Hong Zhai, Yong Chen, and Zhihong Peng. "Preclinical Pharmacokinetics of Triptolide: A Potential Antitumor Drug." Current Drug Metabolism 20, no. 2 (2019): 147–54. http://dx.doi.org/10.2174/1389200219666180816141506.

Full text
Abstract:
Background:Triptolide, a bioactive component in Tripterygium wilfordii extracts, possess strong antiproliferative activity on all 60-National Cancer Institute (NCI) cancer cell lines. However, the widespread use of triptolide in the clinical practice is greatly limited for its multi-organ toxicity and narrow therapeutic window. All the toxic characteristics of triptolide are associated with the pharmacokinetics especially its distribution and accumulation in the target organ.Methods:The literature review was done using PubMed search, SciFinder and Google Scholar databases with specific keyword
APA, Harvard, Vancouver, ISO, and other styles
2

Milan, Laznicek, Laznickova Alice, Cozikova Dagmar, and Velebny Vladimir. "Preclinical pharmacokinetics of radiolabelled hyaluronan." Pharmacological Reports 64, no. 2 (2012): 428–37. http://dx.doi.org/10.1016/s1734-1140(12)70784-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Clarke, Stephen J., Philip J. Beale, and Laurent P. Rivory. "Clinical and Preclinical Pharmacokinetics of Raltitrexed." Clinical Pharmacokinetics 39, no. 6 (2000): 429–43. http://dx.doi.org/10.2165/00003088-200039060-00004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sparreboom, Alex, Olaf van Tellingen, Willem J. Nooijen, and Jos H. Beijnen. "Preclinical pharmacokinetics of paclitaxel and docetaxel." Anti-Cancer Drugs 9, no. 1 (1998): 1–17. http://dx.doi.org/10.1097/00001813-199801000-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tsun, Chang. "Preclinical and clinical pharmacokinetics of pirmenol." American Journal of Cardiology 59, no. 16 (1987): H15—H19. http://dx.doi.org/10.1016/0002-9149(87)90139-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

García-Quintanilla, Laura, Andrea Luaces-Rodríguez, María Gil-Martínez, et al. "Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration." Pharmaceutics 11, no. 8 (2019): 365. http://dx.doi.org/10.3390/pharmaceutics11080365.

Full text
Abstract:
Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical pharmacokinetic data that were obtained in different studies with intravitreal bevacizumab, ranibizumab, and aflibercept has been conducted. Moreover, the factors that can influence the vitreous pharmacokinetics of these drugs, as well as the methods that were used in the studies for analytical determination, have been ex
APA, Harvard, Vancouver, ISO, and other styles
7

Holt, Jonathon D. S., David Cameron, Nicola Dias, et al. "The Sheep as a Model of Preclinical Safety and Pharmacokinetic Evaluations of Candidate Microbicides." Antimicrobial Agents and Chemotherapy 59, no. 7 (2015): 3761–70. http://dx.doi.org/10.1128/aac.04954-14.

Full text
Abstract:
ABSTRACTWhen developing novel microbicide products for the prevention of HIV infection, the preclinical safety program must evaluate not only the active pharmaceutical ingredient but also the product itself. To that end, we applied several relatively standard toxicology study methodologies to female sheep, incorporating an assessment of the pharmacokinetics, safety, tolerability, and local toxicity of a dapivirine-containing human vaginal ring formulation (Dapivirine Vaginal Ring-004). We performed a 3-month general toxicology study, a preliminary pharmacokinetic study using drug-loaded vagina
APA, Harvard, Vancouver, ISO, and other styles
8

Pasipanodya, Jotam, and Tawanda Gumbo. "An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future." Antimicrobial Agents and Chemotherapy 55, no. 1 (2010): 24–34. http://dx.doi.org/10.1128/aac.00749-10.

Full text
Abstract:
ABSTRACTAntimicrobial pharmacokinetic-pharmacodynamic (PK/PD) science and clinical trial simulations have not been adequately applied to the design of doses and dose schedules of antituberculosis regimens because many researchers are skeptical about their clinical applicability. We compared findings of preclinical PK/PD studies of current first-line antituberculosis drugs to findings from several clinical publications that included microbiologic outcome and pharmacokinetic data or had a dose-scheduling design. Without exception, the antimicrobial PK/PD parameters linked to optimal effect were
APA, Harvard, Vancouver, ISO, and other styles
9

Grigoleit, H. G., and P. Grigoleit. "Pharmacology and preclinical pharmacokinetics of peppermint oil." Phytomedicine 12, no. 8 (2005): 612–16. http://dx.doi.org/10.1016/j.phymed.2004.10.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Heglund, I. F., Å. A. Michelet, W. F. Blazak, K. Furuhama, and E. Holtz. "Preclinical Pharmacokinetics and General Toxicology of Iodixanol." Acta Radiologica 36, no. 399_suppl (1995): 69–82. http://dx.doi.org/10.1177/0284185195036s39909.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Preclinical pharmacokinetics"

1

Kearbey, Jeffrey Dale. "Preclinical pharmacokinetics and skeletal pharmacology of a selective androgen receptor modulator." Connect to this title online, 2004. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1085168433.

Full text
Abstract:
Thesis (Ph. D.)--Ohio State University, 2004.<br>Document formatted into pages; contains xvii, 162 p. Includes bibliographical references. Abstract available online via OhioLINK's ETD Center; full text release delayed at author's request until 2005 May 24.
APA, Harvard, Vancouver, ISO, and other styles
2

Kearbey, Jeffrey D. "Preclinical pharmacokinetics and skeletal pharmacology of a selective androgen receptor modulator." The Ohio State University, 2004. http://rave.ohiolink.edu/etdc/view?acc_num=osu1085168433.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dave, Nimita D. "Brain/Brain Tumor Pharmacokinetics and Pharmacodynamics of Letrozole." University of Cincinnati / OhioLINK, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1368013158.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tsakalozou, Eleftheria. "PRECLINICAL AND CLINICAL DEVELOPMENT OF THE LIPOPHILIC CAMPTOTHECIN ANALOGUE AR-67." UKnowledge, 2013. http://uknowledge.uky.edu/pharmacy_etds/18.

Full text
Abstract:
AR-67 is a lipophilic third generation camptothecin analogue, currently under early stage clinical trials. It acts by targeting Topoisomerase 1 (Top1), a nuclear enzyme essential for DNA replication and transcription and is present in two forms, the pharmacologically active lipophilic lactone and the charged carboxylate. In oncology patients participating in a phase I clinical trial, AR-67 lactone was the predominant species in plasma. Similarly to other camptothecins, the identified dose-limiting toxicities for AR-67 were neutropenia, thrombocytopenia and fatigue. In addition, in vitro metabo
APA, Harvard, Vancouver, ISO, and other styles
5

Aimiuwu, Josephine Eki. "Modulation of Pharmacologic Effects of 5-Azacytidine by Ribonucleotide Reductase Antisense GTI-2040." The Ohio State University, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=osu1292851882.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hing, Jeremy P. "The application of non-linear mixed effects modelling to toxicokinetic data : population pharmacokinetics in preclinical studies." Thesis, University of Newcastle Upon Tyne, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.394740.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Burger, A. M., Paul M. Loadman, D. E. Thurston, R. Schultz, H. H. Fiebig, and Michael C. Bibby. "Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119)." Italian Society of Chemotherapy and the Italian Federation of Human and Animal Mycopathology, 2007. http://hdl.handle.net/10454/4571.

Full text
Abstract:
no<br>The pyrrolobenzodiazepine monomer DRH-417 is a member of the anthramycin group of anti-tumor antibiotics that bind covalently to the N2 of guanine within the minor groove of DNA. DRH-417 emerged from the EORTC-Drug Discovery Committee and NCI 60 cell line in vitro screening programs as a potent antiproliferative agent with differential sensitivity towards certain cancer types such as melanoma, breast and renal cell carcinoma (mean IC(50) = 3 nM). DRH-417 was therefore tested for in vivo activity. The maximum tolerated dose (MTD) was established as 0.5 mg/kg given i.p. Marked anti-tumor a
APA, Harvard, Vancouver, ISO, and other styles
8

Ur-Rehman, Tofeeq. "Controlled release gel formulations and preclinical screening of drug candidates." Doctoral thesis, Umeå universitet, Kemiska institutionen, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-40489.

Full text
Abstract:
Simple gel formulations may be applied to enhance the systemic and local exposure of potential compounds. The aim of this thesis is the development and characterization of controlled release formulations based on thermo-reversible poloxamer gels, which are suitable for novel drug delivery applications.  In particular co-solvents (DMSO, ethanol), mucoadhesive polymers (chitosan, alginate) and salts (sodium tripolyphosphate, CaCl2) have been used to enhance the applications of poloxamer 407 (P407) formulations in preclinical animal studies. The impact of these additives on the micellization and
APA, Harvard, Vancouver, ISO, and other styles
9

Chen, Chunli. "Pharmacokinetic-Pharmacodynamic Evaluations and Experimental Design Recommendations for Preclinical Studies of Anti-tuberculosis Drugs." Doctoral thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-318845.

Full text
Abstract:
Tuberculosis is an ancient infectious disease and a leading cause of death globally. Preclinical research is important for defining drugs and regimens which should be carried forward to human studies. This thesis aims to characterize the population pharmacokinetics and exposure-response relationships of anti-tubercular drugs alone and in combinations, and to suggest experimental designs for preclinical settings. The population pharmacokinetics of rifampicin, isoniazid, ethambutol and pyrazinamide were described for the first time in two mouse models. This allowed for linking the population pha
APA, Harvard, Vancouver, ISO, and other styles
10

Jiang, Nan Verfasser], and Dieter [Akademischer Betreuer] [Willbold. "Preclinical pharmacokinetics and cerebral distribution of D-enantiomeric peptides for the treatment of Alzheimer’s disease / Nan Jiang ; Betreuer: Dieter Willbold." Düsseldorf : Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf, 2018. http://d-nb.info/1150918845/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Preclinical pharmacokinetics"

1

Tse, Francis L. S. Preclinical drug disposition: A laboratory handbook. M. Dekker, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Evaluation of drug candidates for preclinical development: Pharmacokinetics, metabolism, pharmaceutics, and toxicology. John Wiley & Sons, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Han, Chao. Evaluation of drug candidates for preclinical development: Pharmacokinetics, metabolism, pharmaceutics, and toxicology. John Wiley & Sons, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Translational ADMET for drug therapy: Principles, methods, and pharmaceutical applications. John Wiley & Sons, Inc., 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

High throughput bioanalytical sample preparation: Methods and automation strategies. Elsevier, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Flavonoid Pharmacokinetics Methods Of Analysis Preclinical And Clinical Pharmacokinetics Safety And Toxicology. John Wiley & Sons, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

1948-, Gad Shayne C., ed. Preclinical development handbook. John Wiley & Sons, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wang, Binghe, Chao Han, and Charles B. Davis. Evaluation of Drug Candidates for Preclinical Development: Pharmacokinetics, Metabolism, Pharmaceutics, and Toxicology. Wiley & Sons, Incorporated, John, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chao, Han, Davis Charles B, and Wang Binghe PhD, eds. Evaluation of drug candidates for preclinical development: Pharmacokinetics, metabolism, pharmaceutics, and toxicology. John Wiley & Sons, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gad, Shayne Cox. Preclinical Development Handbook: Toxicology. Wiley & Sons, Incorporated, John, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Preclinical pharmacokinetics"

1

Yáñez, Jaime A., Casey L. Sayre, and Neal M. Davies. "Preclinical Pharmacokinetics of Flavonoids." In FLAVONOID PHARMACOKINETICS. John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118468524.ch4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Caro, Carlos, M. Carmen Muñoz-Hernández, Manuel Pernia Leal, and María Luisa García-Martín. "In Vivo Pharmacokinetics of Magnetic Nanoparticles." In Preclinical MRI. Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7531-0_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Paxton, James W. "Interrelationship between Pharmacokinetics and Metabolism." In Preclinical Development Handbook. John Wiley & Sons, Inc., 2007. http://dx.doi.org/10.1002/9780470249031.ch30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Malik, Santosh, Ananya Ghosh, Rout George Kerry, and Jyoti Ranjan Rout. "Nanotechnology in Preclinical Pharmacokinetics." In Advances in Pharmaceutical Biotechnology. Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-2195-9_30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

El-Kattan, Ayman, and Manthena Varma. "Preclinical Pharmacokinetics: Industrial Perspective." In Mass Spectrometry Handbook. John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118180730.ch5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ibrahim, Mariam, and Lucila Garcia-Contreras. "Preclinical Pharmacokinetics of Antitubercular Drugs." In Drug Delivery Systems for Tuberculosis Prevention and Treatment. John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118943182.ch7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Burger, Angelika M., and Heinz-Herbert Fiebig. "Preclinical Screening for New Anticancer Agents." In Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-734-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Branch, Robert A., and Edwin K. Jackson. "Preclinical Pharmacodynamics of Antihypertensives." In Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. Springer US, 1993. http://dx.doi.org/10.1007/978-1-4757-1520-0_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Levy, Gerhard. "The Case for Preclinical Pharmacodynamics." In Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. Springer US, 1993. http://dx.doi.org/10.1007/978-1-4757-1520-0_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mukherjee, Asoke, Conrad Chen, Lucy Jean, and Claude B. Coutinho. "Preclinical Pharmacodynamics of Anti-Inflammatory Drugs." In Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. Springer US, 1993. http://dx.doi.org/10.1007/978-1-4757-1520-0_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Preclinical pharmacokinetics"

1

Leal, Mauricio, Joann Wentland, Tracey Clark, et al. "Abstract C117: Preclinical pharmacokinetics of an antibody-drug conjugate targeting 5T4." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-c117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Casulleras, Maria Jove, Jade Spencer, Paul Loadman, et al. "Abstract 4926: Preclinical intratumoral pharmacokinetics (PK) of capecitabine (Cap) given +/- eribulin (Eri)." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4926.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gu, Yi, Yang Sai, Jian Wang, et al. "Abstract 3371: Preclinical disposition and pharmacokinetics of volitinib, a novel selective cMet inhibitor ." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3371.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Shah, Neal, Chris E. Adkins, Afroz S. Mohammad, and Paul R. Lockman. "Abstract 1832: Bioluminescent pharmacokinetics of luciferin in preclinical brain metastases of breast cancer models." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-1832.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chikkanna, Dinesh, Kishore Narayanan, Sunil Panigrahi, et al. "Abstract 4086: Preclinical evaluation of pharmacokinetics, pharmacodynamics and efficacy of the dual CD73-A2AR Inhibitors." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4086.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chikkanna, Dinesh, Kishore Narayanan, Sunil Panigrahi, et al. "Abstract 4086: Preclinical evaluation of pharmacokinetics, pharmacodynamics and efficacy of the dual CD73-A2AR Inhibitors." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4086.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Valic, Michael S., Wenlei Jiang, Lili Ding, et al. "Abstract 1947: Modelling of lipid-based nanoparticle pharmacokinetics and tumor accumulation using preclinical models of ovarian cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1947.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Valic, Michael S., Wenlei Jiang, Lili Ding, et al. "Abstract 1947: Modelling of lipid-based nanoparticle pharmacokinetics and tumor accumulation using preclinical models of ovarian cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1947.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chikkanna, Dinesh, Sunil Kumar Panigrahi, Sujatha Rajagopalan, et al. "Abstract 1392: Preclinical In vivo evaluation of efficacy, pharmacokinetics and pharmacodynamics of novel PRMT5 inhibitors in multiple tumor models." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1392.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Feng, Ying, Yuqiao Shen, Don Musson, Huiyu Zhou, Oriane Scholler, and Leonard E. Post. "Abstract B67: Correlation of pharmacokinetics (PK), pharmacodynamics (PD) and in vivo antitumor activity of BMN 673 in preclinical models." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-b67.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Preclinical pharmacokinetics"

1

Noker, Patricia E. Preclinical Pharmacodynamic and Pharmacokinetic Studies of Investigational New Drugs. Defense Technical Information Center, 1995. http://dx.doi.org/10.21236/ada307633.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Noker, Patricia E. Preclinical Pharmacodynamic and Pharmacokinetic Studies of Investigational New Drugs. Defense Technical Information Center, 2004. http://dx.doi.org/10.21236/ada425594.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Noker, Patricia. Preclinical Pharmacodynamic and Pharmacokinetic Studies of Investigational New Drugs. Defense Technical Information Center, 1993. http://dx.doi.org/10.21236/ada274309.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Preclinical pharmacokinetics' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography